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Purpose: Loteprednol etabonate (LE) is approved by the US FDA in a suspension and ointment 
form (0.5%) for the treatment of postoperative ocular inflammation. This study examined the 
gel formulation of LE, an improved, nonsettling formulation with a lower preservative level 
and a more physiologic pH.
Patients and methods: This multicenter, double-masked, parallel-group, vehicle-controlled 
study randomized patients aged $18 years with postoperative anterior chamber cell 
(ACC) $ grade 2 following uncomplicated cataract surgery to either LE gel or vehicle four 
times a day for 14 days. Primary efficacy end points included the proportion of patients with 
complete resolution of ACC and grade 0 (no) pain by postoperative day 8. Secondary efficacy 
end points included complete resolution and change from baseline in ACC and flare (individual 
and combined), and grade 0 pain at each visit. Safety end points included treatment-emergent 
adverse events, ocular symptoms, changes in intraocular pressure (IOP) and visual acuity, and 
biomicroscopy and funduscopy findings.
Results: A total of 407 patients were randomized to treatment (n = 206, LE gel; n = 201, vehicle). 
At day 8, 31.1% (64) of LE-treated patients and 13.9% (28) of vehicle-treated patients had com-
plete resolution of ACC (P , 0.001), and 75.7% (156) of LE-treated patients and 45.8% (92) 
of vehicle-treated patients had grade 0 pain (P , 0.001). Secondary efficacy end points also 
favored LE gel. Fewer patients treated with LE gel required rescue medication (10.7% versus 
42.3%) prior to day 15, and fewer had an ocular adverse event (16.0% versus 28.9%, P = 0.002). 
No drug-related adverse effects were reported more than once in the LE group. Mean IOP 
decreased in both treatment groups; one patient in the LE group demonstrated a clinically 
significant increase ($10 mm Hg) in IOP that was not considered drug-related. Visual acuity 
and funduscopy findings were similar between treatments.
Conclusion: LE gel 0.5% was efficacious and safe in treating postoperative inflammation and 
pain in this clinical study.
Keywords: cataract surgery, corticosteroids, gel, loteprednol etabonate, postoperative 
inflammation, postoperative pain
Introduction
Cataract surgery is a common procedure undergone by millions of patients worldwide.1 
Surgical trauma to the eye, however, often results in an inflammatory response. This 
response is characterized by the release of phospholipids from cell membranes, 
culminating in the production of chemical inflammatory mediators such as pros-
taglandins and leukotrienes, and the recruitment of neutrophils and macrophages 
to the site of trauma. This inflammation usually manifests as perilimbal injection, 
and inflammatory cells and flare in the anterior chamber along with hyperalgesia.1,2 
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This inflammation, although usually self-limited, may result 
in serious sequelae, such as capsular opacification and cystoid 
macular edema (CME).3,4 To prevent these outcomes, anti-
inflammatory agents are administered postsurgically. The 
most commonly administered class of anti-inflammatory 
agents is topical corticosteroids.
Corticosteroids have been used to treat ocular inflammation 
for over 50 years.5 They offer relief from a broad range of signs 
and symptoms of ocular inflammation and are used in a variety 
of ocular inflammatory conditions. However, they carry a risk 
of side effects, particularly an increase in intraocular pressure 
(IOP).6,7 If left untreated, this increase in IOP could lead to corti-
costeroid-induced ocular hypertension and eventually glaucoma. 
Cantrill et al demonstrated that IOP increases are particularly 
common with older corticosteroids such as dexamethasone.8
Loteprednol etabonate (LE), a unique ester-based corti-
costeroid, was first approved as an ocular anti-inflammatory 
agent by the US FDA in 1998. It has since steadily evolved 
into a commonly prescribed topical ocular corticosteroid, 
including for inflammation occurring after cataract surgery. 
LE differs from other ocular corticosteroids in that the ketone 
group in the carbon-20 position of the traditional predniso-
lone structure is replaced by an ester. This substitution is the 
result of retrometabolic drug design, intended to produce a 
drug that is converted into inactive metabolites after exert-
ing its effects at the glucocorticoid receptor.9,10 This quick 
transformation to an inactive form results in fewer side 
effects and smaller increases in IOP, making it an ideal can-
didate for treating ocular inflammation. LE has been shown 
to have the lipophilicity required for tissue penetration and 
a glucocorticoid receptor–binding affinity that is 4.3 times 
that of dexamethasone, allowing the drug to maintain potent 
anti-inflammatory activity along with decreased side effects.11 
Clinical studies have demonstrated the efficacy and safety of 
LE in its suspension and ointment forms for the treatment of 
inflammation and pain after cataract surgery.12–14 It has also 
been shown to be safe and efficacious in the treatment of 
numerous other ocular inflammatory conditions, including 
but not limited to anterior uveitis, giant papillary conjuncti-
vitis, and seasonal allergic conjunctivitis.15–20
The present study was designed to assess the efficacy 
and safety of a gel formulation of LE versus its vehicle 
in the treatment of inflammation and pain occurring 
after cataract surgery. The gel formulation is designed to 
increase surface retention through the use of polycarbo-
phil and includes the demulcents glycerin and propylene 
glycol. LE gel is a nonsettling suspension that provides 
consistent dose uniformity without shaking. The pH range 
of 6.0–6.5, is closer to physiologic pH than the current LE 
suspension. Finally, the concentration of the preservative 
used, benzalkonium chloride (BAK), was reduced from 
0.01% to 0.003%.
Methods
Study design
This randomized, double-masked, parallel-group study 
evaluated the efficacy and safety of the gel formulation 
of LE against its vehicle. Ethical approval was obtained 
from Schulman Associates Institutional Review Board in 
Cincinnati, OH, or Ethik-Kommission in Saarbrucken, 
Germany. The study was conducted in accordance with 
good clinical practice, as described in the ICH Harmonised 
Tripartite Guidelines for Good Clinical Practice; FDA 
regulation 21 CFR parts 50, 54, 56, and 312, 42 USC 282(j); 
applicable local regulations; and the Declaration of Helsinki. 
All patients provided written informed consent.
Participants
The study enrolled patients from 20 investigative sites in the 
US and two investigative sites in Germany, and included 
patients $18 years planning to undergo routine uncompli-
cated cataract surgery (phacoemulsification with posterior 
chamber intraocular lens implantation) not combined with 
any other surgery. Only patients who in the investigators’ 
opinion had potential postoperative pinhole Snellen visual 
acuity (VA) of at least 20/200 in the study eye were enrolled. 
Female patients of childbearing potential were included 
only if they had negative urine pregnancy tests at screening. 
Further inclusion criteria on postoperative day 1 ensured 
that only patients with postoperative anterior chamber cell 
(ACC) $ grade 2 (6–15 cells) were included.
Patients expected to require concurrent ocular therapy 
either with nonsteroidal anti-inflammatory drugs (NSAIDs), 
mast cell stabilizers, antihistamines, or decongestants during 
the 18 days following cataract surgery or those that had used 
any of the above within 2 days prior to surgery were excluded 
from this study. Also excluded were patients expected to 
require systemic NSAIDs (with the exception of #81 mg of 
acetylsalicylic acid), systemic or ocular (either eye) corticos-
teroids, or concurrent ocular therapy with immunosuppres-
sants during the 18 days following cataract surgery or who 
had used ocular immunosuppressants within 30 days prior 
to surgery; having a history of chronic generalized systemic 
disease or with severe ocular conditions; monocular patients; 
and patients with elevated IOP ($21 mm Hg), uncontrolled 
glaucoma, known hypersensitivity to the study drug or any 
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of its components; or patients currently undergoing treatment 
for glaucoma in the study eye.
Study treatments and assessments
The investigational product in this study was LE gel, manu-
factured by Bausch and Lomb (Tampa, FL), and containing 
LE 0.5%, and the preservative BAK 0.003%. The vehicle 
preparation matched the investigational product in concen-
tration, amount, and formulation for all inactive ingredients 
and preservative, but did not contain LE. The investigators, 
patients, and other personnel involved in the monitoring or 
conduct of the study were masked to study treatment. For 
masking purposes, equal volumes of both the test drug and 
vehicle were packaged into identical polyethylene bottles 
and provided in kit boxes (one study kit per patient), each 
with two dropper bottles.
Eligible patients completed seven visits to the clinic 
during the 4-week study period. Visit 1 (the screening visit) 
occurred within 14 days before cataract surgery; patient 
demographics and medical and ophthalmic history were col-
lected, and patient eligibility was assessed. Eligible patients 
underwent cataract surgery by phacoemulsification with 
posterior chamber intraocular lens implantation at visit 2 
(day of surgery). Visit 3 (baseline) occurred 18–34 hours 
postsurgery. At visit 3, patients who had undergone uncom-
plicated surgery and presented with ACC $ grade 2 were 
randomized in a 1:1 ratio to receive masked treatment of 
either LE gel or vehicle. Instillation of the first dose of the 
study medication occurred at the clinic. Subsequently, one 
or two drops of the study drug were instilled by the patient 
in the study eye four times a day (at approximately 4-hour 
intervals) for 14 days. Visits 4 and 5 were on postoperative 
days 3 and 8, respectively. The fourth dose instilled on the 
day before visit 6 (postoperative day 15) was the last dose. 
Visit 7 was a posttreatment follow-up, performed on postop-
erative day 18. In order to assess compliance of administra-
tion, patients recorded the date and time of each study-drug 
administration in a diary. Patients brought their study drug 
and diary to the clinic at visits 4–6, at which times the study 
drug was weighed for accountability and patient diaries 
reviewed to assess compliance of administration. Patients 
could be placed on anti-inflammatory rescue medication(s) 
at the investigators’ discretion any time during the study. 
Patients requiring rescue medication discontinued study 
medication; however, they were followed up until the end 
of the study. The use of topical antibiotics was permitted, 
provided they were not formulated as a fixed-dose combina-
tion with a steroid.
Investigators assessed ocular signs and symptoms, 
pinhole Snellen VA, and IOP at screening (visit 1) and all 
postoperative visits (visits 3–7). Ocular signs (cells, flare, cili-
ary flush, chemosis, eyelid erythema, palpebral conjunctival 
injection, bulbar conjunctival injection, corneal staining, cor-
neal edema, hyphema, posterior synechiae, and anterior vitre-
ous haze) were evaluated through slit-lamp biomicroscopy. 
Symptoms (pain, photophobia, itching, tearing, dryness, and 
discharge) were assessed by the investigator through direct 
patient inquiry. IOP was measured using a Goldmann appla-
nation tonometer (or an equivalent technique). In addition, 
study-gel comfort was assessed at visits 4–6. Funduscopy 
was performed at screening (visit 1) and postoperative 
day 15 (visit 6) only. Assessments for adverse events (AEs) 
and concomitant medications were done at each study visit 
(visits 1–7). Baseline AE assessments were carried out 1 day 
postoperatively (visit 2) to avoid confounding immediate 
procedure-related AEs with treatment-emergent (TE) AEs. 
Therefore, TEAEs were either new events that were not 
present at baseline or AEs that subsequently worsened from 
baseline. All TEAEs were summarized by severity and rela-
tionship to study treatment.
ACC and anterior chamber flare were both graded on a 
scale of 0–4 (cells: 0 = no cells, 1 = 1–5 cells, 2 = 6–15 cells, 
3 = 16–30 cells, 4 = $30 cells; flare: 0 = none, 1 = mild, 
2 = moderate, 3 = severe, 4 = very severe) using a 1 × 1-mm 
high-power-field slit beam. Ciliary flush, hyphema, and 
posterior synechiae were graded as either absent or present, 
while chemosis, eyelid erythema, palpebral conjunctival 
injection, bulbar conjunctival injection, corneal staining, 
corneal edema, and anterior vitreous haze were graded on a 
scale of 0–3, with 0 being absent/none and 3 severe.   Ocular 
pain was defined as an unpleasant sensation in the eye 
including foreign body sensation, throbbing, stabbing, or 
aching, and was based on a 0–5 scale (0 = none, 1 = minimal, 
2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe). 
Photophobia, itching, tearing, dryness, and discharge were 
graded on a 0–3 scale, with 0 being absent and 3 severe. 
Study-gel comfort was also graded on a 0–3 scale, with 0 
being none and 3 severe.
Outcome measures
The primary efficacy end points were the proportion of study 
eyes with complete resolution of ACC and the proportion 
of study eyes with grade 0 (no) pain at postoperative day 8 
(visit 5). The secondary efficacy end points were the propor-
tion of study eyes with complete resolution of ACC and flare, 
both individually and combined, at each visit, grade 0 pain 
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at each visit, and change from baseline to each follow-up 
visit in the severity of ACC and flare, both separately and 
combined.
Tolerability end points included ocular symptoms and 
study-gel comfort. Safety end points included the incidence 
of AEs, change in IOP, VA, and biomicroscopy and fun-
duscopy findings.
Statistical methods
Approximately 400 participants were planned to be ran-
domized, with 200 patients per treatment group. A total of 
200 patients in the LE gel group would yield approximately 
166 LE gel patients treated for the full duration of 14 days, 
if a 17% rescue medication and discontinuation rate was 
assumed, estimated from rates reported in previous similar 
studies.14 Using the asymptotic Pearson chi-squared test, 
on day 8 a total of 200 patients per treatment group would 
yield 97% and 99% power for detecting a difference in the 
rates of complete resolution of ACC at postoperative day 8 
and grade 0 pain, respectively, assuming population rates 
estimated from previous LE postoperative studies.
The intention-to-treat (ITT) population comprised 
all patients randomly assigned to receive one of the two 
treatments; the safety population comprised all patients 
who had received at least one dose of the study drug. The 
per-protocol (PP) population comprised those patients who 
remained in the study through day 8 and did not deviate from 
the protocol in any way likely to seriously affect the primary 
outcome of the study. End-point analyses were carried out 
for the ITT population.
The primary efficacy end-point analyses of resolution 
of ACC and grade 0 pain were carried out by testing both 
the difference in proportion of study eyes with complete 
resolution of ACC and the difference in the rates of grade 
0 pain between treatments on day 8, using the asymptotic 
Pearson chi-squared statistic and a two-sided alpha = 0.05 
level. Patients with missing data or placed on rescue medi-
cation prior to the visit being summarized were considered 
treatment failures in the analysis. Similar analyses were 
conducted for complete resolution of ACC and flare com-
bined and for flare separately at day 8, and for resolution of 
ACC, flare, ACC and flare combined, and grade 0 pain at 
all other postoperative visits. Both continuous and discrete 
variables by treatment and by visit were used to assess the 
change from baseline for ACC, flare, and composite ACC 
and flare; these were analyzed by carrying the last observa-
tion forward for missing data or patients placed on rescue 
medication.
Tolerability end points of gel-comfort assessment and 
ocular symptoms were summarized by using discrete sum-
mary statistics by visit and by treatment group. The difference 
in severity of symptoms in the study eye was analyzed, 
excluding patients placed on rescue medication prior to the 
visit being summarized.
Safety end points were summarized by visit and treat-
ment group, and were presented separately for data obtained 
prior to and after receiving rescue medication. Pinhole 
Snellen VA, biomicroscopy measures, and funduscopy mea-
sures were summarized using discrete summary statistics. 
IOP was summarized using both continuous summaries 
(including change from baseline scores and change from 
screening) and discrete summaries (including the propor-
tion of subjects with an increase in IOP $ 10 mm Hg 
from baseline and the proportion of subjects with TE 
IOP $ 30 mm Hg). Nonocular TEAEs were summarized 
using discrete summaries at the subject and event level by 
system organ class and preferred term for each treatment 
group. Ocular TEAEs were summarized for treated eyes 
and fellow eyes separately. All TEAEs were summarized 
by severity and relationship separately.
All statistical analyses were conducted using SAS 
version 9.1 or higher (SAS, Cary, NC).
Results
A total of 407 patients enrolled from 22 centers in the US 
and Germany were randomized (n = 206 in the LE gel 
group and n = 201 in the vehicle group) and included in 
both the ITT and safety populations. Of these, 400 patients 
(n = 204 in the LE gel group and n = 196 in the vehicle 
groups) completed the study. The primary reasons for dis-
continuation included AEs (n = 1 for LE gel, diverticulitis; 
n = 1 for vehicle group, increased IOP), investigator 
decision (n = 2 for vehicle group), failure to follow study 
procedures (n = 1 for vehicle group), and other (n = 1 for 
each group). Figure 1 provides a detailed description of 
participant flow. Thirty-four (8.4%) patients had major 
protocol deviations, leaving 373 patients (n = 187 in the 
LE gel group and n = 186 in the vehicle group) in the PP 
population.
Table 1 provides details on the patient demographics. 
A total of 73.7% patients were white and 57.2% were 
female. The mean ± standard deviation (SD) age of the 
study population was 68.9 ± 9.62 years, with an overall age 
range of 30–89 years. Similar ocular and nonocular medi-
cal histories were recorded between treatment groups in the 
ITT population. For all the study populations analyzed, 
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demographic and baseline characteristics were similar 
between treatment groups and across study centers.
Mean ± SD baseline (postoperative day 1, visit 3) ACC 
severity was 2.3 ± 0.49 in the LE gel group and 2.3 ± 0.46 in 
the vehicle group, with more than 99% of subjects having 
grade 2 (6–15 cells) or 3 (16–30 cells) ACC at baseline. 
Mean ± SD flare severity was 1.0 ± 0.62 and 1.1 ± 0.69, 
while mean ± SD combined ACC and flare were 3.3 ± 0.84 
and 3.3 ± 0.89, respectively. At baseline, 50.5% of patients in 
the LE gel group and 50.2% of patients in the vehicle group 
reported $ grade 1 (minimal) pain.
A total of 185 (45.5%) patients required rescue medica-
tion (NSAIDs and/or corticosteroids) during the study, with 
twice as many patients in the vehicle group compared to the 
LE gel group requiring rescue medication (61.2% [123] vs 
30.1% [62]). The cumulative number of patients requiring 
rescue medication in the LE gel group and vehicle groups, 
respectively, was six (2.9%) and 47 (23.4%) by postoperative 
day 8 (visit 5), and 22 (10.7%) and 85 (42.3%) by postopera-
tive day 15 (visit 6). All other rescue medication was initiated 
after the 2-week study treatment ended.
Nearly all patients – 203 patients (99.0%) in the LE 
gel group and 184 patients (99.5%) in the vehicle group – 
provided complete diary data and reported administering four 
doses (±20%) per day through postoperative day 8.
Efficacy
Primary efficacy end points
When missing values and data from patients placed on rescue 
medication were imputed as failures, 31.1% (64) of patients 
in the LE gel group and 13.9% (28) of patients in the vehicle 
group had complete resolution of ACC at day 8 (visit 5). This 
17.1% treatment difference significantly favored the LE gel 
group (95% confidence interval: 8.7%, 25.6%; P , 0.001). 
Grade 0 pain was reported in 75.7% (156) of patients in the 
LE gel group and 45.8% (92) of patients in the vehicle group. 
The 30% between-group treatment difference was statisti-
cally significant in favor of LE gel (95% confidence interval: 
20.4%, 39.5%; P , 0.001). Similar results were obtained 
for the PP population; 32.6% (61) of patients in the LE gel 
group and 14.0% (26) of patients in the vehicle group had 
complete resolution of ACC (P , 0.001); while 76.5% (143) 
Total patients enrolled
(n = 407)
Intent-to-treat/safety population
loteprednol etabonate gel group
(n = 206)
Completed (n = 204)
Adverse event (n = 1)
Other 0.5% (n = 1)
Failure to follow study procedures
(n = 1)
Adverse event (n = 1)
Other (n = 1)
Investigator decision (n=2)
Completed (n = 196)
Intent-to-treat/safety population
vehicle group
(n = 201)
Discontinuations (n = 2):
Discontinuations (n = 5):
Figure 1 Participant flow.
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of patients in the LE gel group and 45.2% (84) of patients in 
the vehicle group had grade 0 pain (P , 0.001). The primary 
end points and treatment differences observed in the ITT and 
PP populations are shown in Figure 2.
Secondary end points
Secondary end points were analyzed for the ITT population 
only. Table 2 shows the proportion of patients with resolu-
tion of ACC, resolution of flare, resolution of ACC and flare 
combined, and grade 0 pain on postoperative days 3, 8, 15, 
and 18 (visits 4–7). With the exception of day 3 resolution 
of ACC and day 3 resolution of ACC and flare combined, all 
secondary end points significantly favored the LE gel group 
(P # 0.006). Figure 3 shows the mean change from baseline 
in ACC and flare, both individually and combined, on post-
operative days 3–18 (visits 4–7). Mean change from baseline 
in ACC, anterior chamber flare, and ACC and flare severity 
combined were significantly better in the LE gel group com-
pared to the vehicle group at all visits (P # 0.002).
Tolerability
The tolerability of the study medication was judged from 
assessments of ocular symptoms of discharge, dryness, itch-
ing, pain, photophobia, and tearing at each postoperative visit, 
and as gel comfort at postoperative visits from days 3–15. 
Ocular pain, photophobia, and tearing – primarily mild – 
were reported at baseline by 50.4%, 57.2%, and 42.0% of 
patients, respectively. Excluding patients placed on rescue 
medication, analysis of these symptoms at postoperative 
follow-up visits showed that fewer patients treated with LE 
gel reported pain (P , 0.001 at days 3 and 8, and P = 0.005 
at day 15), photophobia (P = 0.006 at day 3 and P = 0.002 at 
day 8), and tearing (P = 0.001, 0.007, and 0.037 at days 3, 8, 
and 15 respectively). The majority of patients had no dis-
charge, dryness, or itching at baseline, and these symptoms 
either improved or did not change from baseline in both 
treatment groups at follow-up postoperative visits.
Drop comfort was assessed at postoperative visits from 
days 3–15 as drop sensation (none, mild, moderate, or 
severe). At each of these visits, more than 85% patients in 
each group reported drop sensation as “none.” There were 
no reports of severe sensation at any visit or group, and 
moderate sensation was reported by less than 2% patients 
in either group at all visits.
Safety
Mean ± SD treatment exposure was 13.2 ± 2.33 days in the 
LE gel group and 10.2 ± 4.56 days in the vehicle group. The 
proportion of patients with at least one ocular TEAE prior 
to rescue medication use was 16.0% ± 33% for the LE gel 
group and 28.9% ± 58% for the vehicle group (P = 0.002). As 
is consistent with cataract surgery, the most common ocular 
TEAEs were ocular inflammation, eye pain, iritis, foreign 
body sensations, and dry eye. Table 3 lists ocular TEAEs 
prior to rescue medication that were considered drug-related. 
The proportion of patients with at least one ocular TEAE 
considered drug-related was 2.4% (5) for the LE gel group 
and 7.5% (15) for the vehicle group. Most drug-related ocular 
TEAEs were mild to moderate in severity, and no specific 
drug-related AE was reported more than once in the LE gel 
group. Blurred vision, a consideration with gel formulations, 
was reported for only one patient (LE vehicle group). One 
patient discontinued the study due to a potentially drug-
related reaction (increased IOP in the vehicle group).
Nonocular TEAEs were reported for 5.8% (12) of patients 
in the LE gel group and 2.5% (5) of patients in the vehicle 
group (P = 0.136). The only nonocular TEAEs reported at 
a rate of at least 1% (n = 2) in any treatment group were 
headache (LE gel, n = 2; vehicle, n = 1) and rash (LE gel, 
n = 2). One nonocular TEAE report of rash (facial) in a patient 
treated with LE gel and one nonocular TEAE report of dry 
mouth were considered potential drug-related   reactions. 
Table  1  Patient  demographics  for  the  intention-to-treat 
population
Loteprednol 
etabonate gel  
(n = 206)
Vehicle 
(n = 201)
Overall  
(n = 407)
Age (years)
    Mean (standard  
  deviation)
68.3 (9.66) 69.4 (9.56) 68.9 (9.62)
    Median (range) 69.0 (30, 89) 71.0 (43, 88) 70.0 (30, 89)
Race, n (%)
    White 151 (73.3%) 149 (74.1%) 300 (73.7%)
    Black/African  
  American
22 (10.7%) 21 (10.4%) 43 (10.6%)
    American indian/ 
  Alaskan
2 (1.0%) 2 (1.0%) 4 (1.0%)
    Asian 28 (13.6%) 25 (12.4%) 53 (13.0%)
    Other race 3 (1.5%) 4 (2.0%) 7 (1.7%)
Gender, n (%)
    Male 82 (39.8%) 92 (45.8%) 174 (42.8%)
    Female 124 (60.2%) 109 (54.2%) 233 (57.2%)
Ethnicity, n (%)
    Not Hispanic  
  and not Latino
189 (91.7%) 181 (90.0%) 370 (90.9%)
    Hispanic or Latino 17 (8.3%) 20 (10.0%) 37 (9.1%)
Country, n (%)
    US 198 (96.1%) 193 (96.0%) 391 (96.1%)
    Germany 8 (3.9%) 8 (4.0%) 16 (3.9%)
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31.1%
13.9%
45.8%
32.6%
76.5%
45.2%
18.6% (95%Cl:
9.7%, 27.5%;
P < 0.001)
31.3% (95%Cl:21.4%,
41.2%; P < 0.001)
14.0%
80% 60% 40% 20% 0%
80% 60% 40% 20% 0%
75.7%
LE gel ( n = 206)
Vehicle ( n = 201)
30.0% (95% Cl:20.4%,
39.5%; P < 0.001)
17.1% (95% Cl:8.7%,
25.6%; P < 0.001)
LE gel ( n = 187)
Vehicle ( n = 186)
Complete resolution of ACC
Grade 0 pain
Complete resolution of ACC
Grade 0 pain
A
B
Figure 2 Proportion of patients with complete resolution of anterior chamber cell (ACC) and grade 0 pain at day 8 (visit 5) in the intention-to-treat population (A) and 
per-protocol population (B).
Abbreviations: ACC, Anterior chamber cell; CI, confidence interval; LE, Loteprednol etabonate.
Five TE nonocular serious AEs were reported by three 
patients in the LE gel group (diverticulitis, cholecystitis, and 
myocardial infarction) and one patient in the vehicle group 
(dehydration and hypokalemia). All TE nonocular serious 
AEs were considered unrelated or unlikely to be related to 
the study drug.
The mean ± SD baseline (postoperative day 1) IOP for 
study eyes was similar between treatment groups (LE gel 
group, 14.8 ± 3.37 mm Hg; vehicle group, 14.4 ± 3.48 mm Hg). 
Figure 4 presents the mean ± SD change in IOP for each 
group from baseline to each postoperative visit through 
day 18. Mean IOP was similar between treatment groups 
and consistently lower than baseline at these visits. One 
patient in the LE gel group exhibited a clinically significant 
increase from baseline in IOP ($10 mm Hg). The increase 
was first observed at the day 15 visit, and because IOP was 
also increased in the untreated fellow eye, the investigator 
did not consider the event treatment-related. One subject 
in the vehicle treatment group had a 6-mm increase in IOP 
reported at the day 15 visit that was assessed as potentially 
drug-related (see Table 3).
Baseline VA ranged from 20/15 to 20/60 for 94.6% of 
study eyes in the LE gel group and 93.0% in the vehicle 
group. As expected after cataract surgery, most patients 
had an improvement in VA at day 18, with VA ranging 
from 20/15 to 20/30 for 88.1% of study eyes in the LE gel 
group and 75.9% in the vehicle group. Few study eyes in 
either treatment group had a reduction of more than two 
lines at days 3–18 (LE gel, n = 9; vehicle, n = 11 at worst 
visit analysis), and there were no between-treatment differ-
ences in VA, with the exception of change from baseline at 
day 8 (significantly worse in the vehicle group, P = 0.032). 
Dilated funduscopy findings were comparable across treat-
ment groups at screening and day 15. No fundus pathology 
was reported for the majority of study eyes, and only four 
study eyes (LE gel, n = 1; vehicle, n = 3) had an increase 
in retinal abnormalities compared to screening, all judged 
clinically insignificant.
As expected, biomicroscopy findings showed few patients 
with worsening ocular signs in the LE gel group. Analysis 
of ocular signs at postoperative follow-up visits prior to 
rescue medication showed that fewer patients in the LE gel 
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group had an increased (worsening) of flare, ciliary flush, 
and bulbar conjunctival injection at days 3–18 (P # 0.048, 
P # 0.014, and P # 0.010, respectively), of corneal edema 
and palpebral conjunctival injection at days 3–15 (P # 0.014 
and P # 0.011, respectively), of ACC at day 3 and day 8 
(P # 0.002), and of chemosis at day 3 (P = 0.002).
Discussion
Results from this multicenter, randomized, double-masked, 
parallel-group study demonstrate that LE gel administered 
four times daily for 14 days was significantly more effective 
than vehicle in resolving inflammation and pain after cataract 
surgery. Significantly more patients receiving LE gel than 
those receiving vehicle had complete resolution of ACC and 
grade 0 pain at day 8 (P , 0.001 for both). In addition, half 
as many patients in the LE gel group as in the vehicle group 
required rescue medication. Results from secondary end 
points, including complete resolution of ACC at days 15 and 
18, grade 0 pain at days 3, 15 and 18, and anterior chamber 
flare at all visits were supportive of the primary efficacy   
findings, with significantly better resolution of inflammation 
and pain in patients receiving LE gel compared to vehicle. 
The finding of significant between-group differences in 
anterior chamber flare beginning as early as day 3 suggests 
that the resolution of ocular flare precedes that of ACC and 
is consistent with observations in previous studies.14
LE gel was shown to be both well tolerated and safe. 
At most postoperative visits, patient reports of ocular pain, 
photophobia, and tearing were significantly better in patients 
treated with LE gel, while symptoms of ocular discharge, dry-
ness, and itching, reported by few patients at baseline, either 
improved or did not change from baseline, with no significant 
differences between treatment groups. The majority (.85%) 
of patients in each group reported no drop sensation. Ocular 
TEAEs were consistent with signs observed after cataract 
surgery, and occurred less frequently, overall, in the LE 
gel group compared to the vehicle group (P = 0.002). Few 
TEAEs were drug-related, and no drug-related TEAE was 
reported more than once in the LE gel group. No patients in 
the LE gel group and only one patient (0.5%) in the vehicle 
group reported blurred vision.
LE gel did not affect IOP. Mean IOP was lower than 
baseline at postoperative days 8, 15 and 18, in both treat-
ment groups; further, only one patient in the LE gel group 
demonstrated a clinically significant increase ($10 mm Hg) 
in IOP, and the finding was considered unrelated to study 
treatment. The lack of significant IOP findings in the LE 
gel group is attributed to the rapid de-esterification of LE 
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Figure 3 Mean +/- standard deviation change from baseline in anterior chamber cell and flare severity, individually and combined, for the loteprednol etabonate (LE) gel and 
vehicle groups (intention-to-treat population).
Notes: Negative values denote an improvement. *(P # 0.002).
to inactive metabolites.9,21 Finally, biomicroscopy findings 
showed few LE patients with worsening ocular signs, while 
dilated funduscopy results and VA measurements were com-
parable across treatment groups.
The efficacy and safety of LE 0.5% has previously been 
established in randomized controlled trials; however, these 
earlier studies assessed alternate formulations of LE, ie, 
a suspension and an ointment.12–14 Two studies evaluated the 
efficacy and safety of LE suspension 0.5% versus placebo in 
the treatment of inflammation following cataract surgery.12,13 
Resolution of anterior chamber inflammation (ACI), repre-
senting the sum of cell and flare severity, was the primary 
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parameter evaluated. A total of 227 patients in the first study 
and 203 patients in the second study with ACI $ 3 (0–9 scale) 
on the first postoperative day were randomized to either LE 
suspension or vehicle administered every 4 hours for 14 days. 
Using last-observation-carried-forward analyses, resolution of 
ACI by the final visit (postoperative day 17) occurred in 64% 
of patients in the LE suspension group, compared with 29% of 
patients in the vehicle groups in the first study (difference of 
35%, P , 0.001), and 55% of patients in the LE suspension 
group, compared with 28% patients in the vehicle group in the 
second study (difference of 27%, P , 0.001). No significant 
difference between groups in the mean change in IOP was 
observed at any treatment interval. A clinically significant 
increase ($10 mm Hg) in IOP was seen in three patients in 
the LE group in the first study and one patient in the vehicle 
group in the second study. Comstock et al performed a pooled 
analysis of data from two randomized controlled trials, each 
comparing the safety and efficacy of LE ointment 0.5% to 
vehicle in the treatment of pain and inflammation follow-
ing cataract surgery.14 Patients (n = 805) with ACI $ 3 on 
the first postoperative day were randomized to either LE 
ointment or vehicle four times daily for 14 days. The primary 
efficacy end points included complete resolution of ACI and 
grade 0 pain at postoperative day 8. Complete resolution of 
ACI was observed in 28% of patients in the LE ointment 
group and 13% of patients in the vehicle group. Further, 
76% and 43% of patients had grade 0 pain at postoperative 
day 8. Both end points significantly favored the LE ointment 
group (P , 0.0001). Clinically significant increases in IOP 
($10 mm Hg) were observed in three patients in the LE oint-
ment group and one patient treated with vehicle.
Despite the use of a less stringent definition for resolu-
tion of inflammation in the LE suspension studies (in the LE 
suspension study, grade 0 ACC was defined as #5 cells and 
grade 0 flare was defined as none-to-trace; while in the LE 
ointment and LE gel studies, grade 0 ACC was defined as no 
cells and grade 0 flare was defined as none) and the use of dif-
ferent statistical analyses across studies, resolution rates for 
LE 0.5% appear consistent across studies. By postoperative 
day 8, similar resolution rates for anterior chamber cells and 
flare combined were seen across all LE formulations – 43% 
and 34% in the LE suspension studies, 28% in the LE oint-
ment study, and 31% in this LE gel study.12–14 Further, both 
the suspension and the ointment formulations demonstrated 
good safety profiles, with few ocular TEAEs reported in 
the studies on these formulations.12–14 Taken together with 
data from earlier trials of LE in suspension and ointment 
forms, data from the present study reinforce the use of LE   
Day 3 Day 8 Day 15 Day 18
LE gel ( n = 206)
Vehicle ( n = 201)
3
2
1
0
m
m
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−1
−2
−3
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−6
Figure 4 Mean +/- standard deviation change from baseline in intraocular pressure for the loteprednol etabonate (LE) gel and vehicle groups (safety population).
Table 3 Drug-related ocular TEAEs prior to rescue medication
LE gel  
(n = 206)
Vehicle  
(n = 201)
Patients with at least one related AE 5 (2.4%) 15 (7.5%)
Total drug-related AEs 5 17
  Eye pain 1 (0.5%) 3 (1.5%)
  Foreign body sensation 1 (0.5%) 3 (1.5%)
  Dry eye 1 (0.5%) 1 (0.5%)
  Eye irritation 1 (0.5%) 2 (1.0%)
  Ocular hyperemia 0 2 (1.0%)
  Photophobia 0 1 (0.5%)
  Punctate keratitis 0 1 (0.5%)
  increased lacrimation 1 (0.5%) 0
  Ocular discomfort 0 2 (1.0%)
  Blurred vision 0 1 (0.5%)
  iOP increased 0 1 (0.5%)
Abbreviations:  LE,  loteprednol  etabonate;  TEAE,  treatment-emergent  adverse 
event; iOP, intraocular pressure.
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as an efficacious and safe ocular anti-inflammatory agent for 
patients undergoing cataract surgery.
The availability of a gel formulation of LE allows physi-
cians an additional choice in dosage forms when treating 
patients with ocular inflammation. The LE gel formulation 
differs from the LE suspension formulation in that it contains 
a lower level of BAK with a more physiologic pH and is non-
settling. A potential advantage of using BAK is the enhanced 
corneal penetration of some drugs caused by epithelial tight 
junction separation.22 On the other hand, long-term use of 
BAK has been reported to impact corneal health or produce 
symptoms similar to dry eye in some patients.23,24 To minimize 
any potential negative impact of BAK, the concentration of 
this preservative in the gel formulation has been reduced rela-
tive to the suspension formulation – from 0.01% to 0.003%. 
This formulation change, along with a pH adjustment to one 
more similar to that of human tears (6.0–6.5 in the current gel 
formulation vs 5.3–5.6 in the nonsettling LE suspension), may 
increase comfort in some patients. Indeed, as indicated ear-
lier, more than 85% of patients reported no discomfort upon 
instillation in either treatment group. Finally, the nonsettling 
LE gel formulation does not require shaking to resuspend the 
drug particles. We believe this may improve ease of use while 
providing consistent dose uniformity.
In conclusion, the results of this study indicate that LE gel 
was safe and effective in the treatment of postoperative inflam-
mation and pain following ocular surgery. The availability of 
a gel formulation of the already well-characterized LE 0.5% 
concentration allows physicians a choice of dosage forms in 
treating ocular inflammation following ocular surgery.
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